Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 13, 2025.

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.

Here are the top 5 biosimilar articles for the week of January 6, 2025.

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry.

No significant difference in the risk of serious infections between etanercept and infliximab biosimilars and their original brand-name medications was identified.

Here are the top 5 biosimilar articles for the week of December 30, 2024.

Here are the top 5 biosimilar articles for the week of December 16, 2024.

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing market share and reducing costs despite initial barriers.

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands led to significant price reductions and increased market share.

Here are the top 5 biosimilar articles for the week of December 9, 2024.

Here are the top 5 biosimilar articles for the week of December 2, 2024.

Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.

Here are the top 5 biosimilar articles for the week of November 25, 2024.

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions.

Here are the top 5 biosimilar articles for the week of November 18, 2024.

Here are the top 5 biosimilar articles for the week of October 28, 2024.

Here are the top 5 biosimilar articles for the week of October 21, 2024.

Here are the top 5 biosimilar articles for the week of October 14, 2024.

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the US, emphasizing partnerships for market growth.

Here are the top 5 biosimilar articles for the week of October 7, 2024.

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus erythematosus (SLE).

Here are the top 5 biosimilar articles for the week of September 30, 2024.

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.

Here are the top 5 biosimilar articles for the week of September 23, 2024.

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.

Here are the top 5 biosimilar articles for the week of September 16, 2024.

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability.

Here are the top 5 biosimilar articles for the week of September 9, 2024.

A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the biosimilar ranibizumab, despite fluid challenges.